0001209191-23-024388.txt : 20230414
0001209191-23-024388.hdr.sgml : 20230414
20230414192038
ACCESSION NUMBER: 0001209191-23-024388
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230412
FILED AS OF DATE: 20230414
DATE AS OF CHANGE: 20230414
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Walker Marlan D
CENTRAL INDEX KEY: 0001820187
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-00100
FILM NUMBER: 23822528
MAIL ADDRESS:
STREET 1: 951 YAMATO ROAD
STREET 2: SUITE 220
CITY: BOCA RATON
STATE: FL
ZIP: 33431
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TherapeuticsMD, Inc.
CENTRAL INDEX KEY: 0000025743
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 870233535
STATE OF INCORPORATION: NV
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 951 YAMATO ROAD, SUITE 220
CITY: BOCA RATON
STATE: FL
ZIP: 33431
BUSINESS PHONE: 561-961-1900
MAIL ADDRESS:
STREET 1: 951 YAMATO ROAD, SUITE 220
CITY: BOCA RATON
STATE: FL
ZIP: 33431
FORMER COMPANY:
FORMER CONFORMED NAME: AMHN, Inc.
DATE OF NAME CHANGE: 20090930
FORMER COMPANY:
FORMER CONFORMED NAME: CROFF ENTERPRISES INC
DATE OF NAME CHANGE: 19970915
FORMER COMPANY:
FORMER CONFORMED NAME: CROFF OIL CO
DATE OF NAME CHANGE: 19920703
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-04-12
0
0000025743
TherapeuticsMD, Inc.
TXMD
0001820187
Walker Marlan D
951 YAMATO ROAD
SUITE 220
BOCA RATON
FL
33431
0
1
0
0
Chief Executive Officer
0
Common Stock
2023-04-12
4
M
0
3030
0.00
A
8999
D
Common Stock
2023-04-12
4
M
0
1010
0.00
A
10009
D
Common Stock
2023-04-12
4
M
0
1734
0.00
A
11743
D
Common Stock
2023-04-12
4
M
0
1734
0.00
A
13477
D
Common Stock
2023-04-12
4
S
0
1170
3.6543
D
12307
D
Performance Stock Units
0.00
2023-04-12
4
M
0
3030
0.00
D
Common Stock
3030
0
D
Restricted Stock Units
0.00
2023-04-12
4
M
0
1010
0.00
D
Common Stock
1010
0
D
Restricted Stock Units
0.00
2023-04-12
4
M
0
1734
0.00
D
Common Stock
1734
3466
D
Performance Stock Units
0.00
2023-04-12
4
M
0
1734
0.00
D
Common Stock
1734
3466
D
The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices of $3.63 through $3.71, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth.
The performance stock units (PSUs) vested upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs would have been forfeited. Each PSU represents a contingent right to receive one share of common stock of the issuer.
Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs vested in three equal installments annually, becoming fully vested on March 30, 2023.
Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025.
The vested performance stock units (PSUs) represent PSUs deemed by the compensation committee to be vested at target due to the change in the issuer's business model. The remaining PSUs vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023. One quarter of the initial PSUs were forfeited based on the failure of the issuer to achieve certain EBITDA milestones for the year ended December 31, 2021. Each PSU represents a contingent right to receive one share of common stock of the issuer.
/s/ Marlan D. Walker
2023-04-14